Sender Company & Partners’s Novavax NVAX Stock Holding History

Sender Company & Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,904	Closed	-$195K	–	336
2025 Q3	$225K	Sell	25,904 -26,075	-50%	-$203K	0.02%	385
2025 Q2	$327K	Buy	+51,979	New	+$344K	0.09%	190

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sender Company & Partners's NVAX Position: Q4 2025 in Review

Sender Company & Partners sold out of Novavax (NVAX) in Q4 2025, closing a stake of 25,904 shares — an estimated $195K sold.

Sender Company & Partners first reported a position in NVAX in Q2 2025 and held it in 2 quarters. The position peaked at $327K in Q2 2025. 235 funds tracked by Wall St. Rank hold NVAX as of Q4 2025.

Sender Company & Partners reported no remaining Novavax position as of Q4 2025 after selling out during the quarter.
Sender Company & Partners sold 25,904 Novavax shares in Q4 2025, an estimated $195K.
Sender Company & Partners first reported a position in Novavax in Q2 2025 and held it in 2 quarters.
Sender Company & Partners's Novavax position peaked at $327K in Q2 2025.
235 funds tracked by Wall St. Rank held Novavax as of Q4 2025.

Based on Sender Company & Partners's 13F filing for Q4 2025, filed 17 Feb 2026.